Company: DMAC
Filing Date: 2025-08-22
Form Type: 424B2
Source: 0001437749-25-027557
Chunk: 12

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-08-22
Form: 424B2
Chunk 12
---
-for-20 consolidation of our common shares, and (vi) on May 31, 2019, to continue our existence from a corporation incorporated under the CBCA into British Columbia under the BCBCA. Our articles were subsequently amended and restated on May 17, 2023 to enhance procedural mechanics and disclosure requirements relating to director nominations made by our shareholders and to provide that only our Board of Directors may fix the number of directors of our Company.

<div align='center'>S-7</div>

THE OFFERING

| Common shares offered by us                        |     | Common shares having an aggregate offering price of up to $100,000,000.                                                                                                                                                                                                                                                                                                                                                  |
| Common shares to be outstanding after the offering |     | Up to 60,433,599 common shares, assuming sales of 17,361,111 common shares in this offering at an assumed offering price of $5.76 per common share, which was the last reported sale price of our common shares on August 19, 2025. The actual number of common shares issued in connection with this offering will vary depending on how many common shares we choose to sell and the prices at which such sales occur. |
| Plan of Distribution                               |     | “At-the-market offering” that may be made from time to time through or to our sales agent, TD Cowen. See “Plan of Distribution” beginning on page S-15 of this prospectus supplement.                                                                                                                                                                                                                                    |
| Use of proceeds                                    |     | We intend to use the net proceeds from this offering to continue our clinical and product development activities for DM199 in preeclampsia and general corporate purposes. See “Use of Proceeds” on page S-12 of this prospectus supplement.                                                                                                                                                                             |
| Risk factors                                       |     | Our business and an investment in our common shares involve significant risks. See “Risk Factors” beginning on page S-9 of this prospectus supplement and the other information included in, or incorporated by reference into, this prospectus supplement and the accompanying prospectus for a discussion of factors that you should consider carefully before investing in our common shares.                         |
| Nasdaq Capital Market symbol                       |     | “DMAC”                                                                                                                                                                                                                                                                                                                                                                                                                   |

The number of our common shares to be outstanding after this offering is based on 43,072,488common shares outstanding as of June 30, 2025, and excludes as of that date the following:

| ● | 5,721,194 common shares reserved for